Shots:
Merck has reported the P-III (KEYNOTE‑C93) trial assessing Keytruda (400mg, IV, Q6W for ~18 cycles) vs carboplatin + paclitaxel in pts (n=299) with dMMR advanced or recurrent endometrial cancer who have not previously been treated with systemic CT
Trial met its 1EP of improved PFS, & showed improvements across ORR, CRR, & DoR; OS (1EP)…
